Vuzix Corporation (NASDAQ:VUZI) represented a move of 1.54 percent or $0.05 per share and closed its previous day trading session at $8.25. 543944 Shares were traded in the last trading session with an Average Volume of 837.33 Million Shares. The stock currently has a Market Capitalization of 206.09 Million.
Vuzix is a supplier of Smart-Glasses and Augmented Reality (AR) technologies and products for the consumer and enterprise markets. The Company’s products include personal display and wearable computing devices that offer users a portable high-quality viewing experience, provide solutions for mobility, wearable displays and virtual and augmented reality.
The stock traded between $ 4.10 and $11.40 over 1-Year time period showing its price to sales ratio of 44.8. Vuzix Corporation (NASDAQ:VUZI).
Right now, the stock has a 50-Day Simple Moving Average of $11.43 and 200-Day Simple Moving Average of $31.55. Its Price to Free Cash Flow is 0 and Price to Book of 11.62.
Analyst’s recommended the stock as 2 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Vuzix Corporation (NASDAQ:VUZI) reported its Actual EPS of $-0.28/share. The analysts offering Earnings Estimates for the company were believing that Vuzix Corporation could bring EPS of $-0.17/share. The difference between Actual EPS and Estimated EPS was -0.11 Percent. Thus showing an Earnings Surprise of -64.7 Percent.
Neogenomics Inc. (NASDAQ:NEO)
In the last trading session, Neogenomics Inc. (NASDAQ:NEO) added its value by 1.08% closing at the price of $7.49. The stock currently has market capitalization of 604.59 Million, with average volume of 344.61 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Neogenomics Inc. (NASDAQ:NEO) is showing beta of 0.58. This particular value of beta suggests that Neogenomics Inc. (NASDAQ:NEO) has historically moved 58% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Neogenomics Inc. (NASDAQ:NEO) is at $-0.35.
The stock currently has RSI of 27.1. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company’s testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States.
Neogenomics Inc. (NASDAQ:NEO) topped its 52-week high price of $11.63 on 09/11/17 and 52-Week Low Price of $ 7.08 on 02/06/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 4.29% and monthly volatility of 3.84% respectively.